Big Pharma Split Corp. Class A

As of December 31, 2025, Big Pharma Split Corp. Class A has 1.30M shares outstanding.

These figures are as of December 31, 2025.

Over the twelve months ended December 31, 2025, Big Pharma Split Corp. Class A posted a return on equity (ROE) of 27.55, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 17.30, measuring how efficiently the asset base is converted into earnings.

As of the close on October 22, 2026, Big Pharma Split Corp. Class A's stock has gained approximately 23.95% over the past 52 weeks. The 50-day moving average sits at 14.89, while the 200-day moving average is 14.31.

Over the twelve months ended December 31, 2025, Big Pharma Split Corp. Class A posted a gross margin of 100.00, reflecting its pricing power and cost economics.

These figures cover the twelve months ended December 31, 2025. The dividend payout ratio of 33.79 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -6.61, meaning Big Pharma Split Corp. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, Big Pharma Split Corp. Class A has an Altman Z-Score of 0.98, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.